The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Novel targets, therapies and combinations in myeloma
In this video, Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, highlights some of the exciting novel therapies and targets emerging in the treatment of multiple myeloma. Prof. Jackson briefly discusses novel drugs that are changing the multiple myeloma treatment landscape, including selinexor, venetoclax, and immunomodulatory imide drugs (IMiDs). To conclude, Prof. Jackson highlights the importance of novel targeted immunotherapies, such as anti-CD38 and anti-BCMA antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor T-cell (CAR-T) therapy, in the treatment of myeloma. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Speaker honoraria engagements: Amgen, Takeda, Johnson & Johnson, Sanofi, Celgene and Roche; Research funding: Takeda, Onyx and Celgene; Advisory Boards: Amgen, Takeda, Johnson & Johnson, Oncopeptides, Pfizer, Sanofi, Celgene, GSK and Roche; Board of directors Myeloma UK.
